Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis.
COVID-19
SARS-CoV-2
meta-analysis
mortality
statins
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
18
03
2021
accepted:
26
05
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
15
7
2021
Statut:
epublish
Résumé
Statins up-regulate angiotensin-converting enzyme 2, the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while also exhibiting pleiotropic antiviral, antithrombotic, and anti-inflammatory properties. Uncertainties exist about their effect on the course of SARS-CoV-2 infection. We sought to systematically review the literature and perform a meta-analysis to examine the association between prior statin use and outcomes of patients with coronavirus disease 2019 (COVID-19). We searched Ovid Medline, Web of Science, Scopus, and the preprint server medRxiv from inception to December 2020. We assessed the quality of eligible studies with the Newcastle-Ottawa quality scale. We pooled adjusted relative risk (aRRs) of the association between prior statin use and outcomes of patients with COVID-19 using the DerSimonian-Laird random-effects model and assessed heterogeneity using the Overall, 19 (16 cohorts and 3 case-control) studies were eligible, with a total of 395 513 patients. Sixteen of 19 studies had low or moderate risk of bias. Among 109 080 patients enrolled in 13 separate studies, prior statin use was associated with a lower risk of mortality (pooled aRR, 0.65 [95% confidence interval {CI}, .56-.77], Cumulative evidence suggests that prior statin use is associated with lower risks of mortality or severe disease in patients with COVID-19. These data support the continued use of statins medications in patients with an indication for lipid-lowering therapy during the COVID-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
Statins up-regulate angiotensin-converting enzyme 2, the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while also exhibiting pleiotropic antiviral, antithrombotic, and anti-inflammatory properties. Uncertainties exist about their effect on the course of SARS-CoV-2 infection. We sought to systematically review the literature and perform a meta-analysis to examine the association between prior statin use and outcomes of patients with coronavirus disease 2019 (COVID-19).
METHODS
METHODS
We searched Ovid Medline, Web of Science, Scopus, and the preprint server medRxiv from inception to December 2020. We assessed the quality of eligible studies with the Newcastle-Ottawa quality scale. We pooled adjusted relative risk (aRRs) of the association between prior statin use and outcomes of patients with COVID-19 using the DerSimonian-Laird random-effects model and assessed heterogeneity using the
RESULTS
RESULTS
Overall, 19 (16 cohorts and 3 case-control) studies were eligible, with a total of 395 513 patients. Sixteen of 19 studies had low or moderate risk of bias. Among 109 080 patients enrolled in 13 separate studies, prior statin use was associated with a lower risk of mortality (pooled aRR, 0.65 [95% confidence interval {CI}, .56-.77],
CONCLUSIONS
CONCLUSIONS
Cumulative evidence suggests that prior statin use is associated with lower risks of mortality or severe disease in patients with COVID-19. These data support the continued use of statins medications in patients with an indication for lipid-lowering therapy during the COVID-19 pandemic.
Identifiants
pubmed: 34258316
doi: 10.1093/ofid/ofab284
pii: ofab284
pmc: PMC8244756
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab284Subventions
Organisme : NIAID NIH HHS
ID : R01 AI110173
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120698
Pays : United States
Organisme : NIAID NIH HHS
ID : R56 AI120698
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Am J Cardiol. 2021 May 1;146:99-106
pubmed: 33539857
Am J Physiol Heart Circ Physiol. 2020 May 1;318(5):H1084-H1090
pubmed: 32228252
Crit Care Med. 2010 May;38(5):1321-8
pubmed: 20308883
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
Endocrine. 2021 Feb;71(2):270-272
pubmed: 33219496
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
Cell Metab. 2020 Aug 4;32(2):176-187.e4
pubmed: 32592657
Stat Methods Med Res. 1993;2(2):121-45
pubmed: 8261254
Eur Heart J. 2020 Jun 7;41(22):2058-2066
pubmed: 32498076
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Infect Dis. 2015 Feb 15;211(4):661-2
pubmed: 25160984
J Am Med Dir Assoc. 2020 Jul;21(7):909-914.e2
pubmed: 32674818
J Stroke Cerebrovasc Dis. 2016 Oct;25(10):2360-7
pubmed: 27292907
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Autoimmun Rev. 2020 Jul;19(7):102569
pubmed: 32376394
J Health Econ Outcomes Res. 2020 Sep 29;7(2):165-174
pubmed: 33043063
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
PLoS One. 2013;8(1):e52929
pubmed: 23349694
Crit Care. 2020 Jul 14;24(1):429
pubmed: 32664990
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Pharmacol Res. 2002 Feb;45(2):147-54
pubmed: 11846628
Lancet Respir Med. 2018 Sep;6(9):691-698
pubmed: 30078618
Crit Care. 2012 Dec 11;16(6):R231
pubmed: 23232151
EClinicalMedicine. 2021 Mar;33:100765
pubmed: 33655204
J Infect Dis. 2012 Jan 1;205(1):13-9
pubmed: 22170954
Am J Respir Crit Care Med. 2005 Mar 15;171(6):606-15
pubmed: 15591471
Front Med (Lausanne). 2020 Nov 17;7:584870
pubmed: 33330541
Arch Intern Med. 2009 Oct 12;169(18):1658-67
pubmed: 19822822
Clin Microbiol Infect. 2019 Mar;25(3):280-289
pubmed: 30472427
J Am Heart Assoc. 2020 Dec 15;9(24):e018475
pubmed: 33092446
Am J Respir Crit Care Med. 2009 Jun 15;179(12):1107-14
pubmed: 19324974
Lancet. 2009 Apr 4;373(9670):1175-82
pubmed: 19329177
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
J Clin Epidemiol. 2008 Oct;61(10):991-6
pubmed: 18538991
PLoS One. 2009 Nov 30;4(11):e8087
pubmed: 19956645
Clin Pharmacol Ther. 2020 Dec;108(6):1185-1194
pubmed: 32910830
BMJ Open. 2020 Dec 4;10(12):e044421
pubmed: 33277291
Am J Ther. 2020 Dec 28;Publish Ahead of Print:
pubmed: 33395057
Clin Exp Pharmacol Physiol. 2010 Nov;37(11):1055-63
pubmed: 20659133
Int J Infect Dis. 2020 Jul;96:615-617
pubmed: 32502659
Immunopharmacol Immunotoxicol. 2021 Feb;43(1):37-50
pubmed: 33406943
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Chest. 2020 Nov;158(5):2130-2135
pubmed: 32710891
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
BMJ Open. 2020 Nov 19;10(11):e040402
pubmed: 33444201
Diabetes Metab. 2021 Mar;47(2):101202
pubmed: 33091555
Am J Physiol Lung Cell Mol Physiol. 2018 Feb 1;314(2):L287-L297
pubmed: 29074491
Pacing Clin Electrophysiol. 2018 Mar;41(3):284-289
pubmed: 29341172
Postgrad Med. 2020 Nov;132(8):749-755
pubmed: 32573311
J Clin Lipidol. 2020 Jul - Aug;14(4):396-397
pubmed: 32682805
Biochem Pharmacol. 2015 Feb 1;93(3):343-51
pubmed: 25482567
N Engl J Med. 2009 Apr 30;360(18):1851-61
pubmed: 19329822
BMJ Open Diabetes Res Care. 2021 Jan;9(1):
pubmed: 33408084
Biochem Biophys Res Commun. 2008 May 2;369(2):344-9
pubmed: 18279660
Thorax. 2010 Dec;65(12):1077-84
pubmed: 20971983
J Am Coll Cardiol. 2005 May 17;45(10):1644-8
pubmed: 15893181
Pathogens. 2020 Sep 17;9(9):
pubmed: 32957539
Am J Ther. 2020 Nov 10;:
pubmed: 33201001
Am J Epidemiol. 2007 Aug 1;166(3):348-54
pubmed: 17504779
Am J Cardiol. 2020 Dec 1;136:149-155
pubmed: 32946859
N Engl J Med. 2014 Oct 30;371(18):1695-703
pubmed: 25268516